Maruho Launches Blood-flow Accelerative/Skin-moisturizing Agent "Hirudoid® Foam 0.3%"
Osaka (Japan), September 13, 2018 - Maruho Co., Ltd ("Maruho", Head Office: Osaka, Japan, President and CEO: Koichi Takagi) announces it launched blood-flow accelerative/skin-moisturizing agent "Hirudoid® Foam 0.3%" (INN: heparinoid, hereinafter referred to as "the product"), in Japan today.
The product is a foam agent (topical aerosol agent) that ejects fine-grained foam from the container and contains the same active ingredients in the same concentration as "Hirudoid®" products currently available. The product is easily spread and can be quickly applied to a wide range of affected areas. Maruho hopes the product will expand treatment options and improve adherence for patients suffering from asteatosis and other skin diseases.
Maruho will continue to contribute to patients suffering from skin diseases by providing a stable supply and promoting the proper use of the product and other approved prescription drug "Hirudoid®" products.
Product profile: Hirudoid® Foam 0.3%
| INN | Heparinoid |
| Formulation/Dose | Topical aerosol containing 3.0mg of heparinoid per 1 gram |
| Indication | Thrombophlebitis (including hemorrhoids), Pain and inflammatory diseases owing to circulatory disturbance (induration and pain after injection), Chilblain, Treatment and prevention of hypertrophic scar or keloid, Keratodermia tylodes palmaris progressiva, Asteatosis, Swelling, hematoma, tendosynovitis, myalgia, arthritis after trauma (bruise, sprain, and/or contusion), Torticollis muscularis (infant) |
| Dosage and Administration |
Usually, apply an appropriate amount of the product to the affected area once to several times a day. |
| NHI Drug Price Standard | 1g 22.20yen |
| Packaging | Can: Liquid concentrate 92g x 10 |
| Date of Approval | February 15, 2018 |
| Date of NHI Price Listing | June 15, 2018 |
| Date of Launch | September 13, 2018 |
| Manufacturer | Maruho Co., Ltd |
About Adherence
The degree to which a patient actively participates in treatment. For a medicine prescribed by a doctor, it refers to the degree that a patient understands the disease, the significance of the medication, and voluntarily maintains the dosage and administration.